VP3.15

VP3.15 is a potent, orally bioavailable and CNS-penetrant dual phosphodiesterase (PDE) 7- glycogen synthase kinase (GSK) 3 inhibitor, with IC50s of 1.59 μM and 0.88 μM for PDE7 and GSK-3, respectively. VP3.15 has neuroprotective and neuroreparative activities, thus as potential combined anti-inflammatory and pro-remyelinating therapies for multiple sclerosis (MS) [1].

Product Specifications

CAS Number

[1281681-54-6]

UNSPSC

12352005

Target

GSK-3; Phosphodiesterase (PDE)

Type

Reference compound

Related Pathways

Metabolic Enzyme/Protease; PI3K/Akt/mTOR; Stem Cell/Wnt

Applications

Neuroscience-Neuromodulation

Field of Research

Neurological Disease

Assay Protocol

https://www.medchemexpress.com/vp3-15.html

Solubility

10 mM in DMSO

Smiles

N1(CC/N=C2N=C(C3=CC=CC=C3)N(C4=CC=CC=C4)S/2)CCOCC1

Molecular Formula

C20H22N4OS

Molecular Weight

366.48

References & Citations

[1]Medina-Rodríguez EM, et al. Promoting in vivo remyelination with small molecules: a neuroreparative pharmacological treatment for Multiple Sclerosis. Sci Rep. 2017 Mar 3;7:43545.